BCL-2 antisense therapy in patients with non-Hodgkin lymphoma

Lancet

Volumn 349, Issue 9059, 1997, Pages 1137-1141

  Webb, A ^a   Cunningham, D ^a   Cotter, F ^c   Clarke, P A ^b   Di Stefano, F ^b   Ross, P ^b   Corbo, M ^c   Dziewanowska, Z ^d  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d Genta Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; LACTATE DEHYDROGENASE; MESSENGER RNA; PHOSPHOROTHIOIC ACID DERIVATIVE; PROTEIN BCL 2;

ADULT; AGED; ANEMIA; APOPTOSIS; ARTICLE; CANCER RECURRENCE; CARDIOTOXICITY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HYPERGLYCEMIA; INFECTION; INFLAMMATION; INJECTION SITE; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOPENIA; LYMPHOCYTOPENIA; LYMPHOMA CELL; MALE; NONHODGKIN LYMPHOMA; OPEN READING FRAME; PRIORITY JOURNAL; PROTO ONCOGENE; SKIN MANIFESTATION; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; TUMOR VOLUME;

EID: 0030888664     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)11103-X     Document Type: Article

References (19)

1. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial memebrane protein that blocks programmed cell death. Nature 1990; 348: 334-36.
2. Miyashita T, Reed JC. Bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 1992; 52: 5407-11.
3. Hermine O, Haioun C, Lepage E, et al. Prognostic significance of Bcl-2 protein expression in aggressive non-Hodgkin's lymphoma: groupe d'etude des lymphomas de l'adulte (GELA). Blood 1996; 87: 265-72.
4. Hill ME, MacLennan KA, Cunningham DC, et al. Prognostic significance of Bcl-2 expression and Bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British national lymphoma investigation study. Blood 1996; 88: 1046-51.
5. Pezzella F, Jones M, Ralfkiaer E, Ersboll J, Gatter KC, Mason DY. Evaluation of Bcl-2 protein expression and 14;18 translocation as prognostic markers in follicular lymphoma. Br J Cancer 1992; 65: 87-89.
6. Cotter FE, Johnson P, Hall P, et al. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene 1994; 9: 3049-55.
7. Cotter FE, Corbo M, Raynaud F, et al. Bcl-2 antisense therapy in lymphoma - in vivo and in vivo mechanisms, efficacy, pharmacokinetic and toxicity studies. IV International conference on malignant lymphoma, Lugano. Ann Oncol 1996; 7: 32(abstr 100).
8. National Cancer Institute: guidelines for reporting of adverse drug reactions: division of cancer treatment. Bethesda, MD: National Cancer Institute, 1988.
9. European Organization for Research and Treatment of Cancer (EORTC). A practical guide to EORTC studies. Place: EORTC, 1994.
10. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
11. Galbraith WM, Hobson WC, Giclas PC, Schechter PJ, Agrawal S. Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res Dev 1994; 4: 201-06.
12. Bishop MR, Iversen PL, Bayever E, et al. Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. J Clin Oncol 1996; 14: 1320-26.
13. Park JR, Bernstein ID, Hockenbery DM. Primitive human hematopoietic precursors express Bcl-x but not Bcl-2. Blood 1995; 86: 868-76.
14. Raynaud F, Orr RIM, Goddard PM, et al. Pharmacokinetics of G3139 an antisense oligodeoxynucleotide to Bcl-2 following intravenous or continuous subcutaneous infusion to mice. J Pharmacol Exp Ther 1997 (in press).
15. Veis DJ, Sorenson CM, Shutter JR, Korsmeyer SJ. Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell 1993; 75: 229-40.
16. Kamada S, Shimono A, Shinto Y, et al. Bcl-2 deficiency in mice leads to pleiotropic abnormalities: accelerated lymphoid cell death in thymus and spleen, polycystic kidney, hair hypopigmentation, and distorted small intestine. Cancer Res 1995; 55: 354-59.
17. Agrawal S. Antisense oligonucleotides: towards clinical trials. Trends Biotechnol 1996; 14: 376-87.
18. Selby P, Patel P, Milan S, et al. Ch1VPP combination chemotherapy for Hodgkin's disease: long-term results. Br J Cancer 1990; 62: 279-85.
19. Stenn KS, Lawrence L, Veis D, et al. Expression of the Bcl-2 protooncogene in the cycling adult mouse hair follicle. J Invest Dermatol 1994; 103: 107-11.